SCHEMBL3593276

SCHEMBL3593276

FC(F)(F)c1cccc2[nH]c(C(Cl)(Cl)Cl)nc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.53
KMT2A Q03164 4/20 0.53
GAA P10253 3/20 0.53
MAPT P10636 2/20 0.53
POLB P06746 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
KDM4E B2RXH2 2/20 0.49
HPGD P15428 1/20 0.49
PARP1 P09874 3/20 0.48
NPSR1 Q6W5P4 2/20 0.43
TRPV1 Q8NER1 1/20 0.43
DRD4 P21917 3/20 0.41
DRD3 P35462 3/20 0.41
DRD2 P14416 2/20 0.41
AXL P30530 1/20 0.41
KIF11 P52732 1/20 0.41
GNRHR P30968 1/20 0.39
ALDH1A1 P00352 1/20 0.39
NPY5R Q15761 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10248490 0.86 MEN1 (0.53) MEN1KMT2AGAAMAPTPOLB
SCHEMBL11835594 0.81 MEN1 (0.64) MEN1KMT2AGAAMAPTPOLB
SCHEMBL17731701 0.81 NPC1 (0.46) MEN1KMT2AGAAMAPTPOLB
SCHEMBL12934190 0.79 PARP1 (0.50) MEN1KMT2AGAAMAPTPOLB
SCHEMBL7701680 0.79 GAA (0.47) MEN1KMT2AGAAMAPTPOLB
SCHEMBL4352212 0.79 MGAM (0.55) GAATDP1ALDH1A1
SCHEMBL31569303 0.79 GAA (0.47) MEN1KMT2AGAAMAPTPOLB
SCHEMBL1422525 0.78 PSMB8 (0.56) MEN1KMT2AGAAMAPTPOLB
SCHEMBL11098192 0.77 MEN1 (0.42) MEN1KMT2AGAAMAPTPOLB
SCHEMBL9504942 0.77 MEN1 (0.63) MEN1KMT2AGAAMAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1643991-B1 BENZIMIDAZOLE CARBOXAMIDES AS RAF KINASE INHIBITORS MERCK PATENT GMBH (DE) 2014-03-12 EP disclosed
EP-1643991-B1 BENZIMIDAZOLE CARBOXAMIDES AS RAF KINASE INHIBITORS MERCK PATENT GMBH (DE) 2014-03-12 EP disclosed
US-7691870-B2 Benzimidazole carboxamides as raf kinase inhibitors MERCK PATENT GMBH (DE) 2010-04-06 US disclosed
US-7691870-B2 Benzimidazole carboxamides as raf kinase inhibitors MERCK PATENT GMBH (DE) 2010-04-06 US disclosed
US-7691870-B2 Benzimidazole carboxamides as raf kinase inhibitors MERCK PATENT GMBH (DE) 2010-04-06 US disclosed
US-20070093532-A1 Benzimidazole carboxamides as raf kinase inhibitors MERCK PATENT GMBH (DE) 2007-04-26 US disclosed
US-20070093532-A1 Benzimidazole carboxamides as raf kinase inhibitors MERCK PATENT GMBH (DE) 2007-04-26 US disclosed
US-20070093532-A1 Benzimidazole carboxamides as raf kinase inhibitors MERCK PATENT GMBH (DE) 2007-04-26 US disclosed
EP-1643991-A1 BENZIMIDAZOLE CARBOXAMIDES AS RAF KINASE INHIBITORS MERCK PATENT GmbH (DE) 2006-04-12 EP disclosed
WO-2005004863-A1 BENZIMIDAZOLE CARBOXAMIDES AS RAF KINASE INHIBITORS MERCK PATENT GMBH (DE) 2005-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093532-A1 Benzimidazole carboxamides as raf kinase inhibitors BRAF, RAF1, ARAF MEN1 2765/4885KMT2A 793/4885GAA 733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.